F-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients_老虎社区_美港股上老虎

F-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients

Benzinga2021-08-12

F-star Therapeutics Inc (NASDAQ:FSTX) has expanded its clinical development strategy for FS118 into checkpoint inhibitor naïve patients.
The new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).
FS118 is a bispecific antibody targeting LAG-3 and PD-L1.
In addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.
F-Star ended the quarter with cash and cash equivalents of $81.6 million.
Price Action: FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

330

BowenDu
·2021-08-13
Like and comment pls
回复
2
举报
1nu
·2021-08-13
help me like and comment :)
回复
5
举报
收起
- FunnyFun:
  Ok
  2021-08-13
  回复
  举报
- Singman:
  pls like too
  2021-08-13
  回复
  举报
卧升龙
·2021-08-13
Ok
回复
4
举报
收起
- JANICELSJ:
  Ok
  2021-08-13
  回复
  举报
Syww
·2021-08-13
[Strong] [Strong]
回复
2
举报
Sonson89
·2021-08-13
K
回复
2
举报
987ce65
·2021-08-13
Ok
回复
3
举报
JimmyLZH
·2021-08-13
👍🏻
回复
3
举报
xremy
·2021-08-13
Another Big... Upupup..
回复
3
举报
white_fangg
·2021-08-13
Like and comment
回复
3
举报
收起
- alexpee98:
  yes babe
  2021-08-13
  回复
  举报
- Pplymm:
  Done. pls like back
  2021-08-13
  回复
  举报
pfudor
·2021-08-13
Ok
回复
2
举报
Andtendo
·2021-08-13
Like and comment please
回复
5
举报
收起
- Pplymm:
  Done. pls like back
  2021-08-13
  回复
  举报
lingnh
·2021-08-13
Ok
回复
5
举报
losty
·2021-08-13
Like please
回复
3
举报
收起
- Jaaaaaaa:
  B
  2021-08-13
  回复
  举报
liangwee888
·2021-08-13
comment
回复
3
举报
收起
- MamaProfit:
  no comment
  2021-08-13
  回复
  举报
PooYen
·2021-08-13
Please like. Thanks [Happy] [Happy] [Happy]
回复
5
举报
收起
- VenomJames:
  Sure
  2021-08-13
  回复
  举报
- eddnesb:
  like pls
  2021-08-13
  回复
  举报
- Pplymm:
  Done. pls like back
  2021-08-13
  回复
  举报
J90
·2021-08-13
Help
回复
2
举报
收起
- liangwee888:
  ok
  2021-08-13
  回复
  举报
J90
·2021-08-13
Yaaaa
回复
5
举报
收起
- Xue91:
  Yahhhh
  2021-08-13
  回复
  举报
Andrew210782
·2021-08-13
Like
回复
6
举报
June_C
·2021-08-13
Wiooo
回复
7
举报
MoreNmore
·2021-08-13
Like
回复
点赞
举报

热议股票

7x24

全部

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/2158268958?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-08-12 23:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2158268958","market":"us","top_or_hot":-1,"title":"F-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients","media":"Benzinga","content":"<ul>\n <li><b>F-star Therapeutics Inc</b>&nbsp;(NASDAQ:FSTX) has&nbsp;expanded its clinical development strategy&nbsp;for FS118 into checkpoint inhibitor naïve patients.</li>\n <li>The new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).</li>\n <li>FS118 is a bispecific antibody targeting LAG-3 and PD-L1.</li>\n <li>In addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.</li>\n <li>F-Star ended the quarter with cash and cash equivalents of $81.6 million.</li>\n <li><b>Price Action:</b>&nbsp;FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.</li>\n</ul>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>F-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nF-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients\n</h2>\n\n<h4 class=\"meta\">\n\n2021-08-12 23:12 北京时间&nbsp;&nbsp;&nbsp;<strong>Benzinga</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>F-star Therapeutics Inc (NASDAQ:FSTX) has expanded its clinical development strategy for FS118 into checkpoint inhibitor naïve patients.\nThe new study will start in 2H of 2021 and include biomarker ...</p>\n\n<a href=\"None\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"FSTX","symbol_name":"F-star Therapeutics, Inc. ","start_time":0,"source_url":null,"article_id":"2158268958","we_media_id":"1052270027","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2158268958","pubTimestamp":1628781141,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Benzinga","introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"summary":"\n","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"FSTX":"F-star Therapeutics, Inc. "},"translate_title":"F-STAR的FS118开发计划将检查点幼稚癌症患者包括在内","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"FSTX":0.9},"content_text":"F-star Therapeutics Inc (NASDAQ:FSTX) has expanded its clinical development strategy for FS118 into checkpoint inhibitor naïve patients.\nThe new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).\nFS118 is a bispecific antibody targeting LAG-3 and PD-L1.\nIn addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.\nF-Star ended the quarter with cash and cash equivalents of $81.6 million.\nPrice Action: FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":894375487,"gmtCreate":1628809618149,"gmtModify":1633689400421,"author":{"id":"3574901428369611","authorId":"3574901428369611","name":"BowenDu","avatar":"https://static.tigerbbs.com/b2b540981c00cc0005e6241f782bd3c5","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3574901428369611","authorIdStr":"3574901428369611"},"htmlText":"Like and comment pls","listText":"Like and comment pls","text":"Like and comment pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/894375487","repostId":2158268958,"repostType":4,"repost":{"id":"2158268958","kind":"highlight","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1628781141,"share":"https://www.laohu8.com/m/news/2158268958?lang=&edition=full","pubTime":"2021-08-12 23:12","market":"us","language":"en","title":"F-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2158268958","media":"Benzinga","summary":"\n","content":"<ul>\n <li><b>F-star Therapeutics Inc</b>&nbsp;(NASDAQ:FSTX) has&nbsp;expanded its clinical development strategy&nbsp;for FS118 into checkpoint inhibitor naïve patients.</li>\n <li>The new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).</li>\n <li>FS118 is a bispecific antibody targeting LAG-3 and PD-L1.</li>\n <li>In addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.</li>\n <li>F-Star ended the quarter with cash and cash equivalents of $81.6 million.</li>\n <li><b>Price Action:</b>&nbsp;FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.</li>\n</ul>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>F-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nF-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-08-12 23:12</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<ul>\n <li><b>F-star Therapeutics Inc</b>&nbsp;(NASDAQ:FSTX) has&nbsp;expanded its clinical development strategy&nbsp;for FS118 into checkpoint inhibitor naïve patients.</li>\n <li>The new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).</li>\n <li>FS118 is a bispecific antibody targeting LAG-3 and PD-L1.</li>\n <li>In addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.</li>\n <li>F-Star ended the quarter with cash and cash equivalents of $81.6 million.</li>\n <li><b>Price Action:</b>&nbsp;FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.</li>\n</ul>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FSTX":"F-star Therapeutics, Inc. "},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2158268958","content_text":"F-star Therapeutics Inc (NASDAQ:FSTX) has expanded its clinical development strategy for FS118 into checkpoint inhibitor naïve patients.\nThe new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).\nFS118 is a bispecific antibody targeting LAG-3 and PD-L1.\nIn addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.\nF-Star ended the quarter with cash and cash equivalents of $81.6 million.\nPrice Action: FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":894344901,"gmtCreate":1628809021803,"gmtModify":1633689409691,"author":{"id":"3577610430427001","authorId":"3577610430427001","name":"1nu","avatar":"https://static.tigerbbs.com/15789a74f3eb14371af59c44a8f71041","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3577610430427001","authorIdStr":"3577610430427001"},"htmlText":"help me like and comment :)","listText":"help me like and comment :)","text":"help me like and comment :)","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/894344901","repostId":2158268958,"repostType":4,"repost":{"id":"2158268958","kind":"highlight","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1628781141,"share":"https://www.laohu8.com/m/news/2158268958?lang=&edition=full","pubTime":"2021-08-12 23:12","market":"us","language":"en","title":"F-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2158268958","media":"Benzinga","summary":"\n","content":"<ul>\n <li><b>F-star Therapeutics Inc</b>&nbsp;(NASDAQ:FSTX) has&nbsp;expanded its clinical development strategy&nbsp;for FS118 into checkpoint inhibitor naïve patients.</li>\n <li>The new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).</li>\n <li>FS118 is a bispecific antibody targeting LAG-3 and PD-L1.</li>\n <li>In addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.</li>\n <li>F-Star ended the quarter with cash and cash equivalents of $81.6 million.</li>\n <li><b>Price Action:</b>&nbsp;FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.</li>\n</ul>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>F-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nF-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-08-12 23:12</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<ul>\n <li><b>F-star Therapeutics Inc</b>&nbsp;(NASDAQ:FSTX) has&nbsp;expanded its clinical development strategy&nbsp;for FS118 into checkpoint inhibitor naïve patients.</li>\n <li>The new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).</li>\n <li>FS118 is a bispecific antibody targeting LAG-3 and PD-L1.</li>\n <li>In addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.</li>\n <li>F-Star ended the quarter with cash and cash equivalents of $81.6 million.</li>\n <li><b>Price Action:</b>&nbsp;FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.</li>\n</ul>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FSTX":"F-star Therapeutics, Inc. "},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2158268958","content_text":"F-star Therapeutics Inc (NASDAQ:FSTX) has expanded its clinical development strategy for FS118 into checkpoint inhibitor naïve patients.\nThe new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).\nFS118 is a bispecific antibody targeting LAG-3 and PD-L1.\nIn addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.\nF-Star ended the quarter with cash and cash equivalents of $81.6 million.\nPrice Action: FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5510239,"gmtCreate":1628809392733,"gmtModify":1635153005923,"authorId":3581664026895626,"author":{"id":3581664026895626,"idStr":"3581664026895626","authorId":3581664026895626,"name":"FunnyFun","avatar":"https://static.tigerbbs.com/e07aca58746125ec6ef6115042d363e9","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":894344901,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"},{"id":5510254,"gmtCreate":1628809470751,"gmtModify":1635153004428,"authorId":3575125836760247,"author":{"id":3575125836760247,"idStr":"3575125836760247","authorId":3575125836760247,"name":"Singman","avatar":"https://static.tigerbbs.com/d770feb757705f2d631d2d5f381ae07b","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":894344901,"type":1,"supId":0,"prevId":0,"content":"pls like <u>too</u>","text":"pls like <u>too</u>","html":"pls like <u>too</u>"}],"langContent":"EN"},{"id":894349901,"gmtCreate":1628808521103,"gmtModify":1633689415526,"author":{"id":"3579730769631306","authorId":"3579730769631306","name":"卧升龙","avatar":"https://static.tigerbbs.com/e01d8942aa5f0e60c802ba77bcd46430","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3579730769631306","authorIdStr":"3579730769631306"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/894349901","repostId":2158268958,"repostType":4,"repost":{"id":"2158268958","kind":"highlight","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1628781141,"share":"https://www.laohu8.com/m/news/2158268958?lang=&edition=full","pubTime":"2021-08-12 23:12","market":"us","language":"en","title":"F-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2158268958","media":"Benzinga","summary":"\n","content":"<ul>\n <li><b>F-star Therapeutics Inc</b>&nbsp;(NASDAQ:FSTX) has&nbsp;expanded its clinical development strategy&nbsp;for FS118 into checkpoint inhibitor naïve patients.</li>\n <li>The new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).</li>\n <li>FS118 is a bispecific antibody targeting LAG-3 and PD-L1.</li>\n <li>In addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.</li>\n <li>F-Star ended the quarter with cash and cash equivalents of $81.6 million.</li>\n <li><b>Price Action:</b>&nbsp;FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.</li>\n</ul>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>F-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nF-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-08-12 23:12</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<ul>\n <li><b>F-star Therapeutics Inc</b>&nbsp;(NASDAQ:FSTX) has&nbsp;expanded its clinical development strategy&nbsp;for FS118 into checkpoint inhibitor naïve patients.</li>\n <li>The new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).</li>\n <li>FS118 is a bispecific antibody targeting LAG-3 and PD-L1.</li>\n <li>In addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.</li>\n <li>F-Star ended the quarter with cash and cash equivalents of $81.6 million.</li>\n <li><b>Price Action:</b>&nbsp;FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.</li>\n</ul>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FSTX":"F-star Therapeutics, Inc. "},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2158268958","content_text":"F-star Therapeutics Inc (NASDAQ:FSTX) has expanded its clinical development strategy for FS118 into checkpoint inhibitor naïve patients.\nThe new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).\nFS118 is a bispecific antibody targeting LAG-3 and PD-L1.\nIn addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.\nF-Star ended the quarter with cash and cash equivalents of $81.6 million.\nPrice Action: FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5510683,"gmtCreate":1628811258294,"gmtModify":1635152965589,"authorId":3579777216498074,"author":{"id":3579777216498074,"idStr":"3579777216498074","authorId":3579777216498074,"name":"JANICELSJ","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":894349901,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"}],"langContent":"EN"},{"id":894340494,"gmtCreate":1628808497618,"gmtModify":1633689415874,"author":{"id":"4087953623473280","authorId":"4087953623473280","name":"Syww","avatar":"https://static.tigerbbs.com/eb83576edbcfb98efcb33d606f168221","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4087953623473280","authorIdStr":"4087953623473280"},"htmlText":"[Strong]&nbsp;[Strong]&nbsp;","listText":"[Strong]&nbsp;[Strong]&nbsp;","text":"[Strong] [Strong]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/894340494","repostId":2158268958,"repostType":4,"repost":{"id":"2158268958","kind":"highlight","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1628781141,"share":"https://www.laohu8.com/m/news/2158268958?lang=&edition=full","pubTime":"2021-08-12 23:12","market":"us","language":"en","title":"F-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2158268958","media":"Benzinga","summary":"\n","content":"<ul>\n <li><b>F-star Therapeutics Inc</b>&nbsp;(NASDAQ:FSTX) has&nbsp;expanded its clinical development strategy&nbsp;for FS118 into checkpoint inhibitor naïve patients.</li>\n <li>The new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).</li>\n <li>FS118 is a bispecific antibody targeting LAG-3 and PD-L1.</li>\n <li>In addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.</li>\n <li>F-Star ended the quarter with cash and cash equivalents of $81.6 million.</li>\n <li><b>Price Action:</b>&nbsp;FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.</li>\n</ul>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>F-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nF-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-08-12 23:12</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<ul>\n <li><b>F-star Therapeutics Inc</b>&nbsp;(NASDAQ:FSTX) has&nbsp;expanded its clinical development strategy&nbsp;for FS118 into checkpoint inhibitor naïve patients.</li>\n <li>The new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).</li>\n <li>FS118 is a bispecific antibody targeting LAG-3 and PD-L1.</li>\n <li>In addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.</li>\n <li>F-Star ended the quarter with cash and cash equivalents of $81.6 million.</li>\n <li><b>Price Action:</b>&nbsp;FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.</li>\n</ul>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FSTX":"F-star Therapeutics, Inc. "},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2158268958","content_text":"F-star Therapeutics Inc (NASDAQ:FSTX) has expanded its clinical development strategy for FS118 into checkpoint inhibitor naïve patients.\nThe new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).\nFS118 is a bispecific antibody targeting LAG-3 and PD-L1.\nIn addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.\nF-Star ended the quarter with cash and cash equivalents of $81.6 million.\nPrice Action: FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":894357765,"gmtCreate":1628808471257,"gmtModify":1633689416936,"author":{"id":"3577445690140943","authorId":"3577445690140943","name":"Sonson89","avatar":"https://static.tigerbbs.com/bb78553b48c28648b70634c067b819ec","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3577445690140943","authorIdStr":"3577445690140943"},"htmlText":"K","listText":"K","text":"K","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/894357765","repostId":2158268958,"repostType":4,"repost":{"id":"2158268958","kind":"highlight","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1628781141,"share":"https://www.laohu8.com/m/news/2158268958?lang=&edition=full","pubTime":"2021-08-12 23:12","market":"us","language":"en","title":"F-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2158268958","media":"Benzinga","summary":"\n","content":"<ul>\n <li><b>F-star Therapeutics Inc</b>&nbsp;(NASDAQ:FSTX) has&nbsp;expanded its clinical development strategy&nbsp;for FS118 into checkpoint inhibitor naïve patients.</li>\n <li>The new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).</li>\n <li>FS118 is a bispecific antibody targeting LAG-3 and PD-L1.</li>\n <li>In addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.</li>\n <li>F-Star ended the quarter with cash and cash equivalents of $81.6 million.</li>\n <li><b>Price Action:</b>&nbsp;FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.</li>\n</ul>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>F-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nF-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-08-12 23:12</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<ul>\n <li><b>F-star Therapeutics Inc</b>&nbsp;(NASDAQ:FSTX) has&nbsp;expanded its clinical development strategy&nbsp;for FS118 into checkpoint inhibitor naïve patients.</li>\n <li>The new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).</li>\n <li>FS118 is a bispecific antibody targeting LAG-3 and PD-L1.</li>\n <li>In addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.</li>\n <li>F-Star ended the quarter with cash and cash equivalents of $81.6 million.</li>\n <li><b>Price Action:</b>&nbsp;FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.</li>\n</ul>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FSTX":"F-star Therapeutics, Inc. "},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2158268958","content_text":"F-star Therapeutics Inc (NASDAQ:FSTX) has expanded its clinical development strategy for FS118 into checkpoint inhibitor naïve patients.\nThe new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).\nFS118 is a bispecific antibody targeting LAG-3 and PD-L1.\nIn addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.\nF-Star ended the quarter with cash and cash equivalents of $81.6 million.\nPrice Action: FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":894357401,"gmtCreate":1628808469903,"gmtModify":1633689417058,"author":{"id":"3582709856792743","authorId":"3582709856792743","name":"987ce65","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3582709856792743","authorIdStr":"3582709856792743"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/894357401","repostId":2158268958,"repostType":4,"repost":{"id":"2158268958","kind":"highlight","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1628781141,"share":"https://www.laohu8.com/m/news/2158268958?lang=&edition=full","pubTime":"2021-08-12 23:12","market":"us","language":"en","title":"F-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2158268958","media":"Benzinga","summary":"\n","content":"<ul>\n <li><b>F-star Therapeutics Inc</b>&nbsp;(NASDAQ:FSTX) has&nbsp;expanded its clinical development strategy&nbsp;for FS118 into checkpoint inhibitor naïve patients.</li>\n <li>The new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).</li>\n <li>FS118 is a bispecific antibody targeting LAG-3 and PD-L1.</li>\n <li>In addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.</li>\n <li>F-Star ended the quarter with cash and cash equivalents of $81.6 million.</li>\n <li><b>Price Action:</b>&nbsp;FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.</li>\n</ul>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>F-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nF-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-08-12 23:12</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<ul>\n <li><b>F-star Therapeutics Inc</b>&nbsp;(NASDAQ:FSTX) has&nbsp;expanded its clinical development strategy&nbsp;for FS118 into checkpoint inhibitor naïve patients.</li>\n <li>The new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).</li>\n <li>FS118 is a bispecific antibody targeting LAG-3 and PD-L1.</li>\n <li>In addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.</li>\n <li>F-Star ended the quarter with cash and cash equivalents of $81.6 million.</li>\n <li><b>Price Action:</b>&nbsp;FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.</li>\n</ul>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FSTX":"F-star Therapeutics, Inc. "},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2158268958","content_text":"F-star Therapeutics Inc (NASDAQ:FSTX) has expanded its clinical development strategy for FS118 into checkpoint inhibitor naïve patients.\nThe new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).\nFS118 is a bispecific antibody targeting LAG-3 and PD-L1.\nIn addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.\nF-Star ended the quarter with cash and cash equivalents of $81.6 million.\nPrice Action: FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":894354323,"gmtCreate":1628808359562,"gmtModify":1631893741825,"author":{"id":"3586863844711073","authorId":"3586863844711073","name":"JimmyLZH","avatar":"https://static.tigerbbs.com/7ecc6de8a47b65c54bcbdca5fe23b697","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3586863844711073","authorIdStr":"3586863844711073"},"htmlText":"👍🏻","listText":"👍🏻","text":"👍🏻","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/894354323","repostId":2158268958,"repostType":4,"repost":{"id":"2158268958","kind":"highlight","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1628781141,"share":"https://www.laohu8.com/m/news/2158268958?lang=&edition=full","pubTime":"2021-08-12 23:12","market":"us","language":"en","title":"F-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2158268958","media":"Benzinga","summary":"\n","content":"<ul>\n <li><b>F-star Therapeutics Inc</b>&nbsp;(NASDAQ:FSTX) has&nbsp;expanded its clinical development strategy&nbsp;for FS118 into checkpoint inhibitor naïve patients.</li>\n <li>The new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).</li>\n <li>FS118 is a bispecific antibody targeting LAG-3 and PD-L1.</li>\n <li>In addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.</li>\n <li>F-Star ended the quarter with cash and cash equivalents of $81.6 million.</li>\n <li><b>Price Action:</b>&nbsp;FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.</li>\n</ul>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>F-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nF-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-08-12 23:12</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<ul>\n <li><b>F-star Therapeutics Inc</b>&nbsp;(NASDAQ:FSTX) has&nbsp;expanded its clinical development strategy&nbsp;for FS118 into checkpoint inhibitor naïve patients.</li>\n <li>The new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).</li>\n <li>FS118 is a bispecific antibody targeting LAG-3 and PD-L1.</li>\n <li>In addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.</li>\n <li>F-Star ended the quarter with cash and cash equivalents of $81.6 million.</li>\n <li><b>Price Action:</b>&nbsp;FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.</li>\n</ul>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FSTX":"F-star Therapeutics, Inc. "},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2158268958","content_text":"F-star Therapeutics Inc (NASDAQ:FSTX) has expanded its clinical development strategy for FS118 into checkpoint inhibitor naïve patients.\nThe new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).\nFS118 is a bispecific antibody targeting LAG-3 and PD-L1.\nIn addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.\nF-Star ended the quarter with cash and cash equivalents of $81.6 million.\nPrice Action: FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":894353468,"gmtCreate":1628807943254,"gmtModify":1633689423623,"author":{"id":"4091425725265930","authorId":"4091425725265930","name":"xremy","avatar":"https://static.tigerbbs.com/eed128399f7a5afff5ef683e5991f030","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4091425725265930","authorIdStr":"4091425725265930"},"htmlText":"Another Big... Upupup..&nbsp;","listText":"Another Big... Upupup..&nbsp;","text":"Another Big... Upupup..","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/894353468","repostId":2158268958,"repostType":4,"repost":{"id":"2158268958","kind":"highlight","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1628781141,"share":"https://www.laohu8.com/m/news/2158268958?lang=&edition=full","pubTime":"2021-08-12 23:12","market":"us","language":"en","title":"F-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2158268958","media":"Benzinga","summary":"\n","content":"<ul>\n <li><b>F-star Therapeutics Inc</b>&nbsp;(NASDAQ:FSTX) has&nbsp;expanded its clinical development strategy&nbsp;for FS118 into checkpoint inhibitor naïve patients.</li>\n <li>The new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).</li>\n <li>FS118 is a bispecific antibody targeting LAG-3 and PD-L1.</li>\n <li>In addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.</li>\n <li>F-Star ended the quarter with cash and cash equivalents of $81.6 million.</li>\n <li><b>Price Action:</b>&nbsp;FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.</li>\n</ul>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>F-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nF-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-08-12 23:12</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<ul>\n <li><b>F-star Therapeutics Inc</b>&nbsp;(NASDAQ:FSTX) has&nbsp;expanded its clinical development strategy&nbsp;for FS118 into checkpoint inhibitor naïve patients.</li>\n <li>The new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).</li>\n <li>FS118 is a bispecific antibody targeting LAG-3 and PD-L1.</li>\n <li>In addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.</li>\n <li>F-Star ended the quarter with cash and cash equivalents of $81.6 million.</li>\n <li><b>Price Action:</b>&nbsp;FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.</li>\n</ul>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FSTX":"F-star Therapeutics, Inc. "},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2158268958","content_text":"F-star Therapeutics Inc (NASDAQ:FSTX) has expanded its clinical development strategy for FS118 into checkpoint inhibitor naïve patients.\nThe new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).\nFS118 is a bispecific antibody targeting LAG-3 and PD-L1.\nIn addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.\nF-Star ended the quarter with cash and cash equivalents of $81.6 million.\nPrice Action: FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":894322882,"gmtCreate":1628807489946,"gmtModify":1633689429568,"author":{"id":"3587098012837997","authorId":"3587098012837997","name":"white_fangg","avatar":"https://static.tigerbbs.com/7bb054ebcc34da2e4209120935bb5774","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3587098012837997","authorIdStr":"3587098012837997"},"htmlText":"Like and comment","listText":"Like and comment","text":"Like and comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/894322882","repostId":2158268958,"repostType":4,"repost":{"id":"2158268958","kind":"highlight","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1628781141,"share":"https://www.laohu8.com/m/news/2158268958?lang=&edition=full","pubTime":"2021-08-12 23:12","market":"us","language":"en","title":"F-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2158268958","media":"Benzinga","summary":"\n","content":"<ul>\n <li><b>F-star Therapeutics Inc</b>&nbsp;(NASDAQ:FSTX) has&nbsp;expanded its clinical development strategy&nbsp;for FS118 into checkpoint inhibitor naïve patients.</li>\n <li>The new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).</li>\n <li>FS118 is a bispecific antibody targeting LAG-3 and PD-L1.</li>\n <li>In addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.</li>\n <li>F-Star ended the quarter with cash and cash equivalents of $81.6 million.</li>\n <li><b>Price Action:</b>&nbsp;FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.</li>\n</ul>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>F-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nF-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-08-12 23:12</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<ul>\n <li><b>F-star Therapeutics Inc</b>&nbsp;(NASDAQ:FSTX) has&nbsp;expanded its clinical development strategy&nbsp;for FS118 into checkpoint inhibitor naïve patients.</li>\n <li>The new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).</li>\n <li>FS118 is a bispecific antibody targeting LAG-3 and PD-L1.</li>\n <li>In addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.</li>\n <li>F-Star ended the quarter with cash and cash equivalents of $81.6 million.</li>\n <li><b>Price Action:</b>&nbsp;FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.</li>\n</ul>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FSTX":"F-star Therapeutics, Inc. "},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2158268958","content_text":"F-star Therapeutics Inc (NASDAQ:FSTX) has expanded its clinical development strategy for FS118 into checkpoint inhibitor naïve patients.\nThe new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).\nFS118 is a bispecific antibody targeting LAG-3 and PD-L1.\nIn addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.\nF-Star ended the quarter with cash and cash equivalents of $81.6 million.\nPrice Action: FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5509988,"gmtCreate":1628807801641,"gmtModify":1635153028484,"authorId":3562397124560737,"author":{"id":3562397124560737,"idStr":"3562397124560737","authorId":3562397124560737,"name":"alexpee98","avatar":"https://static.tigerbbs.com/498f836caa6d2f5edd84d4c77a2d6a1e","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":894322882,"type":1,"supId":0,"prevId":0,"content":"yes babe","text":"yes babe","html":"yes babe"},{"id":5510169,"gmtCreate":1628808998479,"gmtModify":1635153012688,"authorId":3582681835792049,"author":{"id":3582681835792049,"idStr":"3582681835792049","authorId":3582681835792049,"name":"Pplymm","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":894322882,"type":1,"supId":0,"prevId":0,"content":"Done. pls like back ","text":"Done. pls like back ","html":"Done. pls like back "}],"langContent":"EN"},{"id":894329299,"gmtCreate":1628807055811,"gmtModify":1633689433326,"author":{"id":"3579598708934903","authorId":"3579598708934903","name":"pfudor","avatar":"https://static.tigerbbs.com/992e0537af169325ff6d7110d0afa707","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3579598708934903","authorIdStr":"3579598708934903"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/894329299","repostId":2158268958,"repostType":4,"repost":{"id":"2158268958","kind":"highlight","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1628781141,"share":"https://www.laohu8.com/m/news/2158268958?lang=&edition=full","pubTime":"2021-08-12 23:12","market":"us","language":"en","title":"F-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2158268958","media":"Benzinga","summary":"\n","content":"<ul>\n <li><b>F-star Therapeutics Inc</b>&nbsp;(NASDAQ:FSTX) has&nbsp;expanded its clinical development strategy&nbsp;for FS118 into checkpoint inhibitor naïve patients.</li>\n <li>The new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).</li>\n <li>FS118 is a bispecific antibody targeting LAG-3 and PD-L1.</li>\n <li>In addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.</li>\n <li>F-Star ended the quarter with cash and cash equivalents of $81.6 million.</li>\n <li><b>Price Action:</b>&nbsp;FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.</li>\n</ul>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>F-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nF-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-08-12 23:12</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<ul>\n <li><b>F-star Therapeutics Inc</b>&nbsp;(NASDAQ:FSTX) has&nbsp;expanded its clinical development strategy&nbsp;for FS118 into checkpoint inhibitor naïve patients.</li>\n <li>The new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).</li>\n <li>FS118 is a bispecific antibody targeting LAG-3 and PD-L1.</li>\n <li>In addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.</li>\n <li>F-Star ended the quarter with cash and cash equivalents of $81.6 million.</li>\n <li><b>Price Action:</b>&nbsp;FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.</li>\n</ul>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FSTX":"F-star Therapeutics, Inc. "},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2158268958","content_text":"F-star Therapeutics Inc (NASDAQ:FSTX) has expanded its clinical development strategy for FS118 into checkpoint inhibitor naïve patients.\nThe new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).\nFS118 is a bispecific antibody targeting LAG-3 and PD-L1.\nIn addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.\nF-Star ended the quarter with cash and cash equivalents of $81.6 million.\nPrice Action: FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":894320010,"gmtCreate":1628806825830,"gmtModify":1633689434752,"author":{"id":"3577917241557928","authorId":"3577917241557928","name":"Andtendo","avatar":"https://static.tigerbbs.com/a36b92c865704901397ab4e190d5ad8a","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3577917241557928","authorIdStr":"3577917241557928"},"htmlText":"Like and comment please","listText":"Like and comment please","text":"Like and comment please","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/894320010","repostId":2158268958,"repostType":4,"repost":{"id":"2158268958","kind":"highlight","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1628781141,"share":"https://www.laohu8.com/m/news/2158268958?lang=&edition=full","pubTime":"2021-08-12 23:12","market":"us","language":"en","title":"F-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2158268958","media":"Benzinga","summary":"\n","content":"<ul>\n <li><b>F-star Therapeutics Inc</b>&nbsp;(NASDAQ:FSTX) has&nbsp;expanded its clinical development strategy&nbsp;for FS118 into checkpoint inhibitor naïve patients.</li>\n <li>The new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).</li>\n <li>FS118 is a bispecific antibody targeting LAG-3 and PD-L1.</li>\n <li>In addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.</li>\n <li>F-Star ended the quarter with cash and cash equivalents of $81.6 million.</li>\n <li><b>Price Action:</b>&nbsp;FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.</li>\n</ul>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>F-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nF-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-08-12 23:12</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<ul>\n <li><b>F-star Therapeutics Inc</b>&nbsp;(NASDAQ:FSTX) has&nbsp;expanded its clinical development strategy&nbsp;for FS118 into checkpoint inhibitor naïve patients.</li>\n <li>The new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).</li>\n <li>FS118 is a bispecific antibody targeting LAG-3 and PD-L1.</li>\n <li>In addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.</li>\n <li>F-Star ended the quarter with cash and cash equivalents of $81.6 million.</li>\n <li><b>Price Action:</b>&nbsp;FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.</li>\n</ul>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FSTX":"F-star Therapeutics, Inc. "},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2158268958","content_text":"F-star Therapeutics Inc (NASDAQ:FSTX) has expanded its clinical development strategy for FS118 into checkpoint inhibitor naïve patients.\nThe new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).\nFS118 is a bispecific antibody targeting LAG-3 and PD-L1.\nIn addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.\nF-Star ended the quarter with cash and cash equivalents of $81.6 million.\nPrice Action: FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5510171,"gmtCreate":1628809004882,"gmtModify":1635153012577,"authorId":3582681835792049,"author":{"id":3582681835792049,"idStr":"3582681835792049","authorId":3582681835792049,"name":"Pplymm","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":894320010,"type":1,"supId":0,"prevId":0,"content":"Done. pls like back ","text":"Done. pls like back ","html":"Done. pls like back "}],"langContent":"EN"},{"id":894364431,"gmtCreate":1628806715523,"gmtModify":1631888862974,"author":{"id":"4087297789740060","authorId":"4087297789740060","name":"lingnh","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":6,"crmLevelSwitch":0,"idStr":"4087297789740060","authorIdStr":"4087297789740060"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/894364431","repostId":2158268958,"repostType":4,"repost":{"id":"2158268958","kind":"highlight","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1628781141,"share":"https://www.laohu8.com/m/news/2158268958?lang=&edition=full","pubTime":"2021-08-12 23:12","market":"us","language":"en","title":"F-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2158268958","media":"Benzinga","summary":"\n","content":"<ul>\n <li><b>F-star Therapeutics Inc</b>&nbsp;(NASDAQ:FSTX) has&nbsp;expanded its clinical development strategy&nbsp;for FS118 into checkpoint inhibitor naïve patients.</li>\n <li>The new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).</li>\n <li>FS118 is a bispecific antibody targeting LAG-3 and PD-L1.</li>\n <li>In addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.</li>\n <li>F-Star ended the quarter with cash and cash equivalents of $81.6 million.</li>\n <li><b>Price Action:</b>&nbsp;FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.</li>\n</ul>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>F-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nF-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-08-12 23:12</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<ul>\n <li><b>F-star Therapeutics Inc</b>&nbsp;(NASDAQ:FSTX) has&nbsp;expanded its clinical development strategy&nbsp;for FS118 into checkpoint inhibitor naïve patients.</li>\n <li>The new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).</li>\n <li>FS118 is a bispecific antibody targeting LAG-3 and PD-L1.</li>\n <li>In addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.</li>\n <li>F-Star ended the quarter with cash and cash equivalents of $81.6 million.</li>\n <li><b>Price Action:</b>&nbsp;FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.</li>\n</ul>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FSTX":"F-star Therapeutics, Inc. "},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2158268958","content_text":"F-star Therapeutics Inc (NASDAQ:FSTX) has expanded its clinical development strategy for FS118 into checkpoint inhibitor naïve patients.\nThe new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).\nFS118 is a bispecific antibody targeting LAG-3 and PD-L1.\nIn addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.\nF-Star ended the quarter with cash and cash equivalents of $81.6 million.\nPrice Action: FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":894366652,"gmtCreate":1628806184576,"gmtModify":1633689438302,"author":{"id":"3568883640417353","authorId":"3568883640417353","name":"losty","avatar":"https://static.tigerbbs.com/c49f1f2b3571ddd8e83ba724663f8f97","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3568883640417353","authorIdStr":"3568883640417353"},"htmlText":"Like please","listText":"Like please","text":"Like please","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/894366652","repostId":2158268958,"repostType":4,"repost":{"id":"2158268958","kind":"highlight","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1628781141,"share":"https://www.laohu8.com/m/news/2158268958?lang=&edition=full","pubTime":"2021-08-12 23:12","market":"us","language":"en","title":"F-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2158268958","media":"Benzinga","summary":"\n","content":"<ul>\n <li><b>F-star Therapeutics Inc</b>&nbsp;(NASDAQ:FSTX) has&nbsp;expanded its clinical development strategy&nbsp;for FS118 into checkpoint inhibitor naïve patients.</li>\n <li>The new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).</li>\n <li>FS118 is a bispecific antibody targeting LAG-3 and PD-L1.</li>\n <li>In addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.</li>\n <li>F-Star ended the quarter with cash and cash equivalents of $81.6 million.</li>\n <li><b>Price Action:</b>&nbsp;FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.</li>\n</ul>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>F-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nF-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-08-12 23:12</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<ul>\n <li><b>F-star Therapeutics Inc</b>&nbsp;(NASDAQ:FSTX) has&nbsp;expanded its clinical development strategy&nbsp;for FS118 into checkpoint inhibitor naïve patients.</li>\n <li>The new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).</li>\n <li>FS118 is a bispecific antibody targeting LAG-3 and PD-L1.</li>\n <li>In addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.</li>\n <li>F-Star ended the quarter with cash and cash equivalents of $81.6 million.</li>\n <li><b>Price Action:</b>&nbsp;FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.</li>\n</ul>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FSTX":"F-star Therapeutics, Inc. "},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2158268958","content_text":"F-star Therapeutics Inc (NASDAQ:FSTX) has expanded its clinical development strategy for FS118 into checkpoint inhibitor naïve patients.\nThe new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).\nFS118 is a bispecific antibody targeting LAG-3 and PD-L1.\nIn addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.\nF-Star ended the quarter with cash and cash equivalents of $81.6 million.\nPrice Action: FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5509840,"gmtCreate":1628806729657,"gmtModify":1631894244585,"authorId":3570001951488746,"author":{"id":3570001951488746,"idStr":"3570001951488746","authorId":3570001951488746,"name":"Jaaaaaaa","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":894366652,"type":1,"supId":0,"prevId":0,"content":"B","text":"B","html":"B"}],"langContent":"EN"},{"id":894388624,"gmtCreate":1628804720668,"gmtModify":1633689448135,"author":{"id":"3554799941327384","authorId":"3554799941327384","name":"liangwee888","avatar":"https://static.tigerbbs.com/5b494f711d74543d0aebd4ba8cd2e434","vip":1,"crmLevel":7,"crmLevelSwitch":0,"idStr":"3554799941327384","authorIdStr":"3554799941327384"},"htmlText":"comment","listText":"comment","text":"comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/894388624","repostId":2158268958,"repostType":4,"repost":{"id":"2158268958","kind":"highlight","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1628781141,"share":"https://www.laohu8.com/m/news/2158268958?lang=&edition=full","pubTime":"2021-08-12 23:12","market":"us","language":"en","title":"F-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2158268958","media":"Benzinga","summary":"\n","content":"<ul>\n <li><b>F-star Therapeutics Inc</b>&nbsp;(NASDAQ:FSTX) has&nbsp;expanded its clinical development strategy&nbsp;for FS118 into checkpoint inhibitor naïve patients.</li>\n <li>The new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).</li>\n <li>FS118 is a bispecific antibody targeting LAG-3 and PD-L1.</li>\n <li>In addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.</li>\n <li>F-Star ended the quarter with cash and cash equivalents of $81.6 million.</li>\n <li><b>Price Action:</b>&nbsp;FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.</li>\n</ul>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>F-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nF-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-08-12 23:12</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<ul>\n <li><b>F-star Therapeutics Inc</b>&nbsp;(NASDAQ:FSTX) has&nbsp;expanded its clinical development strategy&nbsp;for FS118 into checkpoint inhibitor naïve patients.</li>\n <li>The new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).</li>\n <li>FS118 is a bispecific antibody targeting LAG-3 and PD-L1.</li>\n <li>In addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.</li>\n <li>F-Star ended the quarter with cash and cash equivalents of $81.6 million.</li>\n <li><b>Price Action:</b>&nbsp;FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.</li>\n</ul>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FSTX":"F-star Therapeutics, Inc. "},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2158268958","content_text":"F-star Therapeutics Inc (NASDAQ:FSTX) has expanded its clinical development strategy for FS118 into checkpoint inhibitor naïve patients.\nThe new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).\nFS118 is a bispecific antibody targeting LAG-3 and PD-L1.\nIn addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.\nF-Star ended the quarter with cash and cash equivalents of $81.6 million.\nPrice Action: FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5509826,"gmtCreate":1628806579692,"gmtModify":1635153042346,"authorId":3577432235687566,"author":{"id":3577432235687566,"idStr":"3577432235687566","authorId":3577432235687566,"name":"MamaProfit","avatar":"https://static.tigerbbs.com/71c384811ff2abe860a7f1c6804b88b0","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":894388624,"type":1,"supId":0,"prevId":0,"content":"no comment","text":"no comment","html":"no comment"}],"langContent":"EN"},{"id":894380045,"gmtCreate":1628803957287,"gmtModify":1633689451915,"author":{"id":"3576743360399762","authorId":"3576743360399762","name":"PooYen","avatar":"https://static.tigerbbs.com/90f2bad6620330727869f3a5a51a046a","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3576743360399762","authorIdStr":"3576743360399762"},"htmlText":"Please like. Thanks &nbsp;[Happy]&nbsp;[Happy]&nbsp;[Happy]&nbsp;","listText":"Please like. Thanks &nbsp;[Happy]&nbsp;[Happy]&nbsp;[Happy]&nbsp;","text":"Please like. Thanks [Happy] [Happy] [Happy]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/894380045","repostId":2158268958,"repostType":4,"repost":{"id":"2158268958","kind":"highlight","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1628781141,"share":"https://www.laohu8.com/m/news/2158268958?lang=&edition=full","pubTime":"2021-08-12 23:12","market":"us","language":"en","title":"F-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2158268958","media":"Benzinga","summary":"\n","content":"<ul>\n <li><b>F-star Therapeutics Inc</b>&nbsp;(NASDAQ:FSTX) has&nbsp;expanded its clinical development strategy&nbsp;for FS118 into checkpoint inhibitor naïve patients.</li>\n <li>The new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).</li>\n <li>FS118 is a bispecific antibody targeting LAG-3 and PD-L1.</li>\n <li>In addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.</li>\n <li>F-Star ended the quarter with cash and cash equivalents of $81.6 million.</li>\n <li><b>Price Action:</b>&nbsp;FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.</li>\n</ul>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>F-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nF-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-08-12 23:12</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<ul>\n <li><b>F-star Therapeutics Inc</b>&nbsp;(NASDAQ:FSTX) has&nbsp;expanded its clinical development strategy&nbsp;for FS118 into checkpoint inhibitor naïve patients.</li>\n <li>The new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).</li>\n <li>FS118 is a bispecific antibody targeting LAG-3 and PD-L1.</li>\n <li>In addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.</li>\n <li>F-Star ended the quarter with cash and cash equivalents of $81.6 million.</li>\n <li><b>Price Action:</b>&nbsp;FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.</li>\n</ul>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FSTX":"F-star Therapeutics, Inc. "},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2158268958","content_text":"F-star Therapeutics Inc (NASDAQ:FSTX) has expanded its clinical development strategy for FS118 into checkpoint inhibitor naïve patients.\nThe new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).\nFS118 is a bispecific antibody targeting LAG-3 and PD-L1.\nIn addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.\nF-Star ended the quarter with cash and cash equivalents of $81.6 million.\nPrice Action: FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5509604,"gmtCreate":1628803970081,"gmtModify":1635153061416,"authorId":3580070859233564,"author":{"id":3580070859233564,"idStr":"3580070859233564","authorId":3580070859233564,"name":"VenomJames","avatar":"https://static.tigerbbs.com/70886e65847996bcb0627151be63f811","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":894380045,"type":1,"supId":0,"prevId":0,"content":"<u>Sure</u>","text":"<u>Sure</u>","html":"<u>Sure</u>"},{"id":5509856,"gmtCreate":1628806827200,"gmtModify":1635153039901,"authorId":3579903139528819,"author":{"id":3579903139528819,"idStr":"3579903139528819","authorId":3579903139528819,"name":"eddnesb","avatar":"https://static.tigerbbs.com/7cb1a44cae788badb83f540b30835814","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":894380045,"type":1,"supId":5509604,"prevId":0,"content":"like <u>pls</u>","text":"like <u>pls</u>","html":"like <u>pls</u>"},{"id":5510172,"gmtCreate":1628809016740,"gmtModify":1635153012464,"authorId":3582681835792049,"author":{"id":3582681835792049,"idStr":"3582681835792049","authorId":3582681835792049,"name":"Pplymm","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":894380045,"type":1,"supId":0,"prevId":0,"content":"Done. pls like back ","text":"Done. pls like back ","html":"Done. pls like back "}],"langContent":"EN"},{"id":894315102,"gmtCreate":1628803577906,"gmtModify":1633689454568,"author":{"id":"3581487017513023","authorId":"3581487017513023","name":"J90","avatar":"https://static.tigerbbs.com/59b9bd5153d367d5ee88324bdf6c6003","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3581487017513023","authorIdStr":"3581487017513023"},"htmlText":"Help","listText":"Help","text":"Help","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/894315102","repostId":2158268958,"repostType":4,"repost":{"id":"2158268958","kind":"highlight","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1628781141,"share":"https://www.laohu8.com/m/news/2158268958?lang=&edition=full","pubTime":"2021-08-12 23:12","market":"us","language":"en","title":"F-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2158268958","media":"Benzinga","summary":"\n","content":"<ul>\n <li><b>F-star Therapeutics Inc</b>&nbsp;(NASDAQ:FSTX) has&nbsp;expanded its clinical development strategy&nbsp;for FS118 into checkpoint inhibitor naïve patients.</li>\n <li>The new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).</li>\n <li>FS118 is a bispecific antibody targeting LAG-3 and PD-L1.</li>\n <li>In addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.</li>\n <li>F-Star ended the quarter with cash and cash equivalents of $81.6 million.</li>\n <li><b>Price Action:</b>&nbsp;FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.</li>\n</ul>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>F-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nF-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-08-12 23:12</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<ul>\n <li><b>F-star Therapeutics Inc</b>&nbsp;(NASDAQ:FSTX) has&nbsp;expanded its clinical development strategy&nbsp;for FS118 into checkpoint inhibitor naïve patients.</li>\n <li>The new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).</li>\n <li>FS118 is a bispecific antibody targeting LAG-3 and PD-L1.</li>\n <li>In addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.</li>\n <li>F-Star ended the quarter with cash and cash equivalents of $81.6 million.</li>\n <li><b>Price Action:</b>&nbsp;FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.</li>\n</ul>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FSTX":"F-star Therapeutics, Inc. "},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2158268958","content_text":"F-star Therapeutics Inc (NASDAQ:FSTX) has expanded its clinical development strategy for FS118 into checkpoint inhibitor naïve patients.\nThe new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).\nFS118 is a bispecific antibody targeting LAG-3 and PD-L1.\nIn addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.\nF-Star ended the quarter with cash and cash equivalents of $81.6 million.\nPrice Action: FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5509661,"gmtCreate":1628804740957,"gmtModify":1635153057087,"authorId":3554799941327384,"author":{"id":3554799941327384,"idStr":"3554799941327384","authorId":3554799941327384,"name":"liangwee888","avatar":"https://static.tigerbbs.com/5b494f711d74543d0aebd4ba8cd2e434","vip":1,"crmLevel":7,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":894315102,"type":1,"supId":0,"prevId":0,"content":"<u>ok</u>","text":"<u>ok</u>","html":"<u>ok</u>"}],"langContent":"EN"},{"id":894315325,"gmtCreate":1628803566167,"gmtModify":1633689454690,"author":{"id":"3581487017513023","authorId":"3581487017513023","name":"J90","avatar":"https://static.tigerbbs.com/59b9bd5153d367d5ee88324bdf6c6003","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3581487017513023","authorIdStr":"3581487017513023"},"htmlText":"Yaaaa","listText":"Yaaaa","text":"Yaaaa","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/894315325","repostId":2158268958,"repostType":4,"repost":{"id":"2158268958","kind":"highlight","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1628781141,"share":"https://www.laohu8.com/m/news/2158268958?lang=&edition=full","pubTime":"2021-08-12 23:12","market":"us","language":"en","title":"F-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2158268958","media":"Benzinga","summary":"\n","content":"<ul>\n <li><b>F-star Therapeutics Inc</b>&nbsp;(NASDAQ:FSTX) has&nbsp;expanded its clinical development strategy&nbsp;for FS118 into checkpoint inhibitor naïve patients.</li>\n <li>The new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).</li>\n <li>FS118 is a bispecific antibody targeting LAG-3 and PD-L1.</li>\n <li>In addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.</li>\n <li>F-Star ended the quarter with cash and cash equivalents of $81.6 million.</li>\n <li><b>Price Action:</b>&nbsp;FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.</li>\n</ul>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>F-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nF-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-08-12 23:12</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<ul>\n <li><b>F-star Therapeutics Inc</b>&nbsp;(NASDAQ:FSTX) has&nbsp;expanded its clinical development strategy&nbsp;for FS118 into checkpoint inhibitor naïve patients.</li>\n <li>The new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).</li>\n <li>FS118 is a bispecific antibody targeting LAG-3 and PD-L1.</li>\n <li>In addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.</li>\n <li>F-Star ended the quarter with cash and cash equivalents of $81.6 million.</li>\n <li><b>Price Action:</b>&nbsp;FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.</li>\n</ul>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FSTX":"F-star Therapeutics, Inc. "},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2158268958","content_text":"F-star Therapeutics Inc (NASDAQ:FSTX) has expanded its clinical development strategy for FS118 into checkpoint inhibitor naïve patients.\nThe new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).\nFS118 is a bispecific antibody targeting LAG-3 and PD-L1.\nIn addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.\nF-Star ended the quarter with cash and cash equivalents of $81.6 million.\nPrice Action: FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5509737,"gmtCreate":1628805665894,"gmtModify":1635153050773,"authorId":3582021616632458,"author":{"id":3582021616632458,"idStr":"3582021616632458","authorId":3582021616632458,"name":"Xue91","avatar":"https://static.tigerbbs.com/4d9f9012cc2ef597a6ee7470e2cfb3e1","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":894315325,"type":1,"supId":0,"prevId":0,"content":"Yahhhh","text":"Yahhhh","html":"Yahhhh"}],"langContent":"EN"},{"id":894318550,"gmtCreate":1628803206270,"gmtModify":1633689456356,"author":{"id":"3583140590641923","authorId":"3583140590641923","name":"Andrew210782","avatar":"https://static.tigerbbs.com/0e065afa93f953171dd0eb9aaebbe93b","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3583140590641923","authorIdStr":"3583140590641923"},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/894318550","repostId":2158268958,"repostType":4,"repost":{"id":"2158268958","kind":"highlight","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1628781141,"share":"https://www.laohu8.com/m/news/2158268958?lang=&edition=full","pubTime":"2021-08-12 23:12","market":"us","language":"en","title":"F-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2158268958","media":"Benzinga","summary":"\n","content":"<ul>\n <li><b>F-star Therapeutics Inc</b>&nbsp;(NASDAQ:FSTX) has&nbsp;expanded its clinical development strategy&nbsp;for FS118 into checkpoint inhibitor naïve patients.</li>\n <li>The new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).</li>\n <li>FS118 is a bispecific antibody targeting LAG-3 and PD-L1.</li>\n <li>In addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.</li>\n <li>F-Star ended the quarter with cash and cash equivalents of $81.6 million.</li>\n <li><b>Price Action:</b>&nbsp;FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.</li>\n</ul>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>F-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nF-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-08-12 23:12</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<ul>\n <li><b>F-star Therapeutics Inc</b>&nbsp;(NASDAQ:FSTX) has&nbsp;expanded its clinical development strategy&nbsp;for FS118 into checkpoint inhibitor naïve patients.</li>\n <li>The new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).</li>\n <li>FS118 is a bispecific antibody targeting LAG-3 and PD-L1.</li>\n <li>In addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.</li>\n <li>F-Star ended the quarter with cash and cash equivalents of $81.6 million.</li>\n <li><b>Price Action:</b>&nbsp;FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.</li>\n</ul>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FSTX":"F-star Therapeutics, Inc. "},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2158268958","content_text":"F-star Therapeutics Inc (NASDAQ:FSTX) has expanded its clinical development strategy for FS118 into checkpoint inhibitor naïve patients.\nThe new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).\nFS118 is a bispecific antibody targeting LAG-3 and PD-L1.\nIn addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.\nF-Star ended the quarter with cash and cash equivalents of $81.6 million.\nPrice Action: FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":894331492,"gmtCreate":1628797567916,"gmtModify":1631893551740,"author":{"id":"3574813964437135","authorId":"3574813964437135","name":"June_C","avatar":"https://static.tigerbbs.com/ae77017e1795eeceab087663e5586137","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3574813964437135","authorIdStr":"3574813964437135"},"htmlText":"Wiooo","listText":"Wiooo","text":"Wiooo","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/894331492","repostId":2158268958,"repostType":4,"repost":{"id":"2158268958","kind":"highlight","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1628781141,"share":"https://www.laohu8.com/m/news/2158268958?lang=&edition=full","pubTime":"2021-08-12 23:12","market":"us","language":"en","title":"F-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2158268958","media":"Benzinga","summary":"\n","content":"<ul>\n <li><b>F-star Therapeutics Inc</b>&nbsp;(NASDAQ:FSTX) has&nbsp;expanded its clinical development strategy&nbsp;for FS118 into checkpoint inhibitor naïve patients.</li>\n <li>The new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).</li>\n <li>FS118 is a bispecific antibody targeting LAG-3 and PD-L1.</li>\n <li>In addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.</li>\n <li>F-Star ended the quarter with cash and cash equivalents of $81.6 million.</li>\n <li><b>Price Action:</b>&nbsp;FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.</li>\n</ul>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>F-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nF-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-08-12 23:12</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<ul>\n <li><b>F-star Therapeutics Inc</b>&nbsp;(NASDAQ:FSTX) has&nbsp;expanded its clinical development strategy&nbsp;for FS118 into checkpoint inhibitor naïve patients.</li>\n <li>The new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).</li>\n <li>FS118 is a bispecific antibody targeting LAG-3 and PD-L1.</li>\n <li>In addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.</li>\n <li>F-Star ended the quarter with cash and cash equivalents of $81.6 million.</li>\n <li><b>Price Action:</b>&nbsp;FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.</li>\n</ul>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FSTX":"F-star Therapeutics, Inc. "},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2158268958","content_text":"F-star Therapeutics Inc (NASDAQ:FSTX) has expanded its clinical development strategy for FS118 into checkpoint inhibitor naïve patients.\nThe new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).\nFS118 is a bispecific antibody targeting LAG-3 and PD-L1.\nIn addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.\nF-Star ended the quarter with cash and cash equivalents of $81.6 million.\nPrice Action: FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":894394995,"gmtCreate":1628794114817,"gmtModify":1633689463184,"author":{"id":"4090758549041910","authorId":"4090758549041910","name":"MoreNmore","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"4090758549041910","authorIdStr":"4090758549041910"},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/894394995","repostId":2158268958,"repostType":4,"repost":{"id":"2158268958","kind":"highlight","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1628781141,"share":"https://www.laohu8.com/m/news/2158268958?lang=&edition=full","pubTime":"2021-08-12 23:12","market":"us","language":"en","title":"F-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2158268958","media":"Benzinga","summary":"\n","content":"<ul>\n <li><b>F-star Therapeutics Inc</b>&nbsp;(NASDAQ:FSTX) has&nbsp;expanded its clinical development strategy&nbsp;for FS118 into checkpoint inhibitor naïve patients.</li>\n <li>The new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).</li>\n <li>FS118 is a bispecific antibody targeting LAG-3 and PD-L1.</li>\n <li>In addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.</li>\n <li>F-Star ended the quarter with cash and cash equivalents of $81.6 million.</li>\n <li><b>Price Action:</b>&nbsp;FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.</li>\n</ul>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>F-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nF-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-08-12 23:12</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<ul>\n <li><b>F-star Therapeutics Inc</b>&nbsp;(NASDAQ:FSTX) has&nbsp;expanded its clinical development strategy&nbsp;for FS118 into checkpoint inhibitor naïve patients.</li>\n <li>The new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).</li>\n <li>FS118 is a bispecific antibody targeting LAG-3 and PD-L1.</li>\n <li>In addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.</li>\n <li>F-Star ended the quarter with cash and cash equivalents of $81.6 million.</li>\n <li><b>Price Action:</b>&nbsp;FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.</li>\n</ul>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FSTX":"F-star Therapeutics, Inc. "},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2158268958","content_text":"F-star Therapeutics Inc (NASDAQ:FSTX) has expanded its clinical development strategy for FS118 into checkpoint inhibitor naïve patients.\nThe new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).\nFS118 is a bispecific antibody targeting LAG-3 and PD-L1.\nIn addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.\nF-Star ended the quarter with cash and cash equivalents of $81.6 million.\nPrice Action: FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":330,"commentSize":27,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}